(Q33372127)

English

Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Giuseppe Signoriello

object named as

Giuseppe Signoriello

18

0 references

Vittorio Gebbia

object named as

Vittorio Gebbia

8

0 references

object named as

Sandro Pignata

1

0 references

Massimo Di Maio

object named as

Massimo Di Maio

17

0 references

Giovanni Scambia

2

object named as

Giovanni Scambia

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

author name string

Antonella Savarese

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Enrico Breda

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Paolo Scollo

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Rocco De Vivo

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Emanuela Rossi

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Donato Natale

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Filomena Del Gaizo

10

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Emanuele Naglieri

11

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Antonella Ferro

12

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Pietro Musso

13

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Alfonso Maria D'Arco

14

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Roberto Sorio

15

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Carmela Pisano

16

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Annalisa Annunziata

19

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Francesco Perrone

20

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

MITO Investigators

21

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

language of work or name

0 references

publication date

1 August 2006

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

202

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

copyright license

Creative Commons Attribution 2.0 Generic

1 August 2006

1 reference

April 2022 Public Data File from Crossref

copyright status

1 reference

April 2022 Public Data File from Crossref

Pegylated liposomal doxorubicin and carboplatin in advanced gynecologic tumors: a prospective phase I/II study of the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1553473

21 June 2018

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1553473

21 June 2018

Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1553473

21 June 2018

Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1553473

21 June 2018

Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1553473

21 June 2018

Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1553473

21 June 2018

Tumour uptake of doxorubicin in polyethylene glycol-coated liposomes and therapeutic effect against a xenografted human pancreatic carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1553473

21 June 2018

Impact of doxorubicin on survival in advanced ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1553473

21 June 2018

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1553473

21 June 2018

Carboplatin dosage: prospective evaluation of a simple formula based on renal function

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1553473

21 June 2018

A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-6-202

21 January 2018

Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-6-202

21 January 2018

Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-6-202

21 January 2018

Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-6-202

21 January 2018

Treatment of patients with ovarian carcinoma with pegylated liposomal doxorubicin: analysis of toxicities and predictors of outcome.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1553473

31 October 2018

Inhibition of human ovarian cancer colony formation by adriamycin and its major metabolites

1 reference

https://pubmed.ncbi.nlm.nih.gov/16882344

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis. The Ovarian Cancer Meta-Analysis Project

1 reference

https://pubmed.ncbi.nlm.nih.gov/16882344

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Therapy of human ovarian carcinoma xenografts using doxorubicin encapsulated in sterically stabilized liposomes

1 reference

https://pubmed.ncbi.nlm.nih.gov/16882344

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Doxorubicin encapsulated in sterically stabilized liposomes is superior to free drug or drug-containing conventional liposomes at suppressing growth and metastases of human lung tumor xenografts

1 reference

https://pubmed.ncbi.nlm.nih.gov/16882344

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1471-2407-6-202

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33372127&oldid=2195296557"